JAK1 and psoriatic arthritis: Upadacitinib, an oral, selective Janus kinase 1 (JAK1) inhibitor is approved for use in moderate-to-severe AD as well as other immune-mediated inflammatory conditions, including psoriatic arthritis, ulcerative colitis, and Crohn’s disease.8, –10 JAK inhibitors have broader immunomodulatory properties than Dupilumab and have been found to successfully treat several patients with clinical overlap between AD and psoriasis.11